{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T12:40:59Z","timestamp":1791376859417,"version":"4.3.2"},"update-to":[{"DOI":"10.1002\/14651858.cd006119.pub3","type":"new_version","label":"New version","source":"publisher","updated":{"date-parts":[[2023,8,31]],"date-time":"2023-08-31T00:00:00Z","timestamp":1693440000000}}],"reference-count":138,"publisher":"Wiley","issue":"8","content-domain":{"domain":["wiley.com","cochranelibrary.com"],"crossmark-restriction":true},"short-container-title":[],"DOI":"10.1002\/14651858.cd006119.pub4","type":"journal-article","created":{"date-parts":[[2023,8,31]],"date-time":"2023-08-31T06:36:09Z","timestamp":1693463769000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Evaluation of follow-up strategies for women with epithelial ovarian cancer following completion of primary treatment"],"prefix":"10.1002","volume":"2023","author":[{"given":"Georgia","family":"Zachou","sequence":"additional","affiliation":[{"name":"Gynaecological Oncology; Royal London Hospital, Barts Health NHS Trust; London UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fatima","family":"El-Khouly","sequence":"additional","affiliation":[{"name":"Medical Oncology; Barking, Havering and Redbridge University Hospital NHS Trust; London UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James","family":"Dilley","sequence":"additional","affiliation":[{"name":"Gynaecological Oncology; Royal London Hospital, Barts Health NHS Trust; London UK"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2023,8,31]]},"reference":[{"issue":"1","key":"10.1002\/14651858.CD006119.pub4-BIB0001|cit1","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1097\/IGC.0000000000000877","article-title":"Ovarian cancer follow-up: a preliminary comparison of 2 approaches","volume":"27","author":"Lanceley","year":"2017","journal-title":"International Journal of Gynecological Cancer"},{"issue":"9747","key":"10.1002\/14651858.CD006119.pub4-BIB0002|cit2","doi-asserted-by":"crossref","first-page":"1155","DOI":"10.1016\/S0140-6736(10)61268-8","article-title":"Early versus delayed treatment of relapsed ovarian cancer (MRC OV05\/EORTC 55955): a randomised trial","volume":"376","author":"Rustin","year":"2010","journal-title":"Lancet"},{"issue":"11","key":"10.1002\/14651858.CD006119.pub4-BIB0003|cit3","doi-asserted-by":"crossref","first-page":"1427","DOI":"10.1001\/jamaoncol.2016.1842","article-title":"Use of CA-125 tests and computed tomographic scans for surveillance in ovarian cancer","volume":"2","author":"Esselen","year":"2016","journal-title":"JAMA Oncology"},{"issue":"11","key":"10.1002\/14651858.CD006119.pub4-BIB0004|cit4","doi-asserted-by":"publisher","first-page":"660","DOI":"10.1097\/OGX.0000000000000377","article-title":"Use of CA-125 tests and computed tomographic scans for surveillance in ovarian cancer","volume":"71","author":"Esselen","year":"2017","journal-title":"Obstetrical & Gynecological survey"},{"issue":"2","key":"10.1002\/14651858.CD006119.pub4-BIB0005|cit5","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1016\/j.ygyno.2021.05.024","article-title":"OVPSYCH2: a randomized controlled trial of psychological support versus standard of care following chemotherapy for ovarian cancer","volume":"162","author":"Frangou","year":"2021","journal-title":"Gynecologic Oncology"},{"key":"10.1002\/14651858.CD006119.pub4-BIB0006|cit6","unstructured":"A trial of optimal personalised care after treatment for gynaecological cancer (TOPCAT-G) www.isrctn.com\/ISRCTN45565436?q=ISRCTN45565436"},{"issue":"4","key":"10.1002\/14651858.CD006119.pub4-BIB0007|cit7","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1111\/ajco.12798","article-title":"A randomised controlled trial of a treatment decision-aid for asymptomatic women with rising CA-125 after successful first-line therapy for ovarian cancer","volume":"13","author":"Juraskova","year":"2017","journal-title":"Asia-Pacific Journal of Clinical Oncology"},{"issue":"5","key":"10.1002\/14651858.CD006119.pub4-BIB0008|cit8","doi-asserted-by":"publisher","first-page":"343","DOI":"10.3747\/co.23.3042","article-title":"Follow-up of patients who are clinically disease-free after primary treatment for fallopian tube, primary peritoneal, or epithelial ovarian cancer: a program in evidence-based care guideline adaptation","volume":"23","author":"Le","year":"2016","journal-title":"Current Oncology"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD006119.pub4-BIB0009|cit9","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1097\/01.IGC.0000473498.85773.6e","article-title":"Computed tomography is more sensitive than CA-125 in detecting disease progression in patients with platinum-resistant ovarian cancer: Analysis of the AURELIA trial","volume":"25","author":"Lindeman","year":"2015","journal-title":"International Journal of Gynecological Cancer"},{"issue":"2","key":"10.1002\/14651858.CD006119.pub4-BIB0010|cit10","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1002\/pon.4373","article-title":"Trial of optimal personalised care after treatment for gynaecological cancer (TOPCAT-G): a randomised feasibility trial","volume":"26","author":"Morrison","year":"2017","journal-title":"Psycho-Oncology"},{"issue":"2","key":"10.1002\/14651858.CD006119.pub4-BIB0011|cit11","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1097\/IGC.0000000000001179","article-title":"Trial of optimal personalised care after treatment - gynaecological cancer (TOPCAT-G): a randomized feasibility trial","volume":"28","author":"Morrison","year":"2018","journal-title":"International Journal of Gynecological Cancer"},{"key":"10.1002\/14651858.CD006119.pub4-BIB0012|cit12","unstructured":"Early chemotherapy based on CA 125 level alone compared with delayed chemotherapy in treating patients with recurrent ovarian epithelial, fallopian tube, or primary peritoneal cancer clinicaltrials.gov\/show\/NCT00002895"},{"key":"10.1002\/14651858.CD006119.pub4-BIB0013|cit13","unstructured":"Individualised versus conventional medical follow-up for women after primary treatment for ovarian cancer clinicaltrials.gov\/show\/NCT02298855"},{"key":"10.1002\/14651858.CD006119.pub4-BIB0014|cit14","unstructured":"An individualised and patient-centred follow-up program for women with gynaecological cancer (NEMO) clinicaltrials.gov\/ct2\/show\/record\/NCT03838861"},{"issue":"6","key":"10.1002\/14651858.CD006119.pub4-BIB0015|cit15","doi-asserted-by":"publisher","first-page":"e13325","DOI":"10.1111\/ecc.13325","article-title":"Nurse-led follow-up in survivorship care of gynaecological malignancies \u2013 a randomised controlled trial","volume":"29","author":"Wei","year":"2020","journal-title":"European Journal of Cancer Care"},{"issue":"8","key":"10.1002\/14651858.CD006119.pub4-BIB0016|cit16","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1093\/annonc\/mdr471","article-title":"Follow-up with CA125 after primary therapy of advanced ovarian cancer has major implications for treatment outcome and trial performances and should not be routinely performed","volume":"22","author":"Rustin","year":"2011","journal-title":"Annals of Oncology"},{"issue":"5","key":"10.1002\/14651858.CD006119.pub4-BIB0017|cit17","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1093\/jnci\/85.5.365","article-title":"The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology","volume":"85","author":"Aaronson","year":"1993","journal-title":"Journal of the National Cancer Institut"},{"issue":"1","key":"10.1002\/14651858.CD006119.pub4-BIB0018|cit18","first-page":"85","article-title":"Value of radioimmunoscintigraphy compared to computed tomography in the diagnosis and follow-up of primary ovarian carcinoma","volume":"153","author":"Barzen","year":"1990","journal-title":"R\u00f6Fo:Fortschritte auf dem Gebiete der R\u00f6ntgenstrahlen und derNuklearmedizin"},{"key":"10.1002\/14651858.CD006119.pub4-BIB0019|cit19","doi-asserted-by":"crossref","first-page":"a3147","DOI":"10.1136\/bmj.a3147","article-title":"Comparing hospital and telephone follow-up after treatment for breast cancer: randomised equivalence trial","volume":"338","author":"Beaver","year":"2009","journal-title":"BMJ"},{"issue":"4","key":"10.1002\/14651858.CD006119.pub4-BIB0020|cit20","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1080\/01443610050112084","article-title":"What are the factors associated with the follow-up preferences of women in long-term remission from gynaecological cancer?","volume":"20","author":"Bradley","year":"2000","journal-title":"Journal of Obstetrics and Gynaecology"},{"issue":"1","key":"10.1002\/14651858.CD006119.pub4-BIB0021|cit21","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1016\/j.ygyno.2008.08.033","article-title":"Cytoreductive surgery for recurrent ovarian cancer: a meta-analysis","volume":"112","author":"Bristow","year":"2009","journal-title":"Gynecologic Oncology"},{"issue":"5A","key":"10.1002\/14651858.CD006119.pub4-BIB0022|cit22","first-page":"1353","article-title":"CA-125 monitoring in the management of ovarian cancer","volume":"10","author":"Bruzzone","year":"1990","journal-title":"Anticancer Research"},{"issue":"9","key":"10.1002\/14651858.CD006119.pub4-BIB0023|cit23","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1007\/s12032-017-1026-y","article-title":"Ovarian cancer recurrence and early detection: may HE4 play a key role in this open challenge? A systematic review of literature","volume":"34","author":"Capriglione","year":"2017","journal-title":"Medical Oncology"},{"issue":"4","key":"10.1002\/14651858.CD006119.pub4-BIB0024|cit24","first-page":"347","article-title":"Validity of gynaegnost in the follow-up of patients treated for ovarian cancer","volume":"84","author":"Cerejeira","year":"1989","journal-title":"Revue Fran\u00e7aise de Gyn\u00e9cologie et d'Obst\u00e9trique"},{"issue":"2","key":"10.1002\/14651858.CD006119.pub4-BIB0025|cit25","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1016\/j.ygyno.2008.04.030","article-title":"The role of regular physical examination in the detection of ovarian cancer recurrence","volume":"110","author":"Chan","year":"2008","journal-title":"Gynecologic Oncology"},{"key":"10.1002\/14651858.CD006119.pub4-BIB0026|cit26","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1016\/j.ejogrb.2020.03.028","article-title":"Patient initiated follow up after gynaecological malignancy: national survey of current UK practice","volume":"248","author":"Coleman","year":"2020","journal-title":"European Journal of Obstetrics & Gynecology and Reproductive Biology"},{"issue":"6","key":"10.1002\/14651858.CD006119.pub4-BIB0027|cit27","doi-asserted-by":"crossref","first-page":"972","DOI":"10.1097\/01.psy.0000188402.95398.c0","article-title":"Cancer attributions, distress, and health practices among gynecologic cancer survivors","volume":"67","author":"Costanzo","year":"2005","journal-title":"Psychosomatic Medicine"},{"key":"10.1002\/14651858.CD006119.pub4-BIB0028|cit28","unstructured":"Covidence Veritas Health Innovation"},{"issue":"1-2","key":"10.1002\/14651858.CD006119.pub4-BIB0029|cit29","first-page":"135","article-title":"Clinical significance of cancer antigen 125 (CA 125) in ovarian cancer","volume":"8","author":"Crombach","year":"1985","journal-title":"Cancer Detection and Prevention"},{"key":"10.1002\/14651858.CD006119.pub4-BIB0030|cit30","unstructured":"Cancer Research UK (CRUK) Ovarian cancer fact sheet www.cancerresearchuk.org\/health-professional\/cancerstatistics\/statistics-by-cancer-type\/ovarian-cancer"},{"issue":"3","key":"10.1002\/14651858.CD006119.pub4-BIB0031|cit31","doi-asserted-by":"crossref","first-page":"701","DOI":"10.2214\/ajr.176.3.1760701","article-title":"Role of chest CT in the follow-up of ovarian adenocarcinoma","volume":"176","author":"Dachman","year":"2001","journal-title":"American Journal of Roentgenology"},{"issue":"6","key":"10.1002\/14651858.CD006119.pub4-BIB0032|cit32","doi-asserted-by":"crossref","first-page":"783","DOI":"10.3109\/02841869509127187","article-title":"The role of cul-de-sac aspiration cytology in the follow-up of ovarian cancer","volume":"34","author":"Engblom","year":"1995","journal-title":"Acta Oncologica (Stockholm Sweden)"},{"issue":"15","key":"10.1002\/14651858.CD006119.pub4-BIB0033|cit33","doi-asserted-by":"crossref","first-page":"2104","DOI":"10.1016\/j.ejca.2015.08.001","article-title":"The EUROCARE-5 study on cancer survival in Europe 1999-2007: database, quality checks and statistical analysis methods","volume":"51","author":"Rossi","year":"2015","journal-title":"European Journal of Cancer"},{"issue":"3","key":"10.1002\/14651858.CD006119.pub4-BIB0034|cit34","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1155\/1998\/738321","article-title":"The value of CA 125 and CA72-4 in management of patients with epithelial ovarian cancer","volume":"14","author":"Fayed","year":"1998","journal-title":"Disease Markers"},{"issue":"3A","key":"10.1002\/14651858.CD006119.pub4-BIB0035|cit35","first-page":"1551","article-title":"Evaluation of CA125, physical and radiological findings in follow-up of ovarian cancer patients","volume":"25","author":"Fehm","year":"2005","journal-title":"Anticancer Research"},{"issue":"2","key":"10.1002\/14651858.CD006119.pub4-BIB0036|cit36","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1136\/ijgc-2021-002885","article-title":"Ovarian cancer recurrence detection may not require in-person physical examination: an MSK team ovary study","volume":"32","author":"Feinberg","year":"2022","journal-title":"International Journal of Gynecological Cancer"},{"issue":"11","key":"10.1002\/14651858.CD006119.pub4-BIB0037|cit37","doi-asserted-by":"crossref","first-page":"1325","DOI":"10.1111\/aogs.13396","article-title":"Gynecological cancer patients' attitudes toward follow-up care after cancer treatment: do preferences reflect patients' experience? A cross-sectional questionnaire study","volume":"97","author":"Fidjeland","year":"2018","journal-title":"Acta Obstetricia et Gynecologica Scandinavica"},{"issue":"2","key":"10.1002\/14651858.CD006119.pub4-BIB0038|cit38","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/0090-8258(92)90031-D","article-title":"The concomitant determination of different serum tumor markers in epithelial ovarian cancer: relevance for monitoring the response to chemotherapy and follow-up of patients","volume":"44","author":"Fioretti","year":"1992","journal-title":"Gynecologic Oncology"},{"issue":"1","key":"10.1002\/14651858.CD006119.pub4-BIB0039|cit39","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1136\/jcp.42.1.40","article-title":"Serum placental-like alkaline phosphatase PLAP: a novel combined enzyme linked immunoassay for monitoring ovarian cancer","volume":"42","author":"Fisken","year":"1989","journal-title":"Journal of Clinical Pathology"},{"key":"10.1002\/14651858.CD006119.pub4-BIB0040|cit40","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/j.ejogrb.2017.04.016","article-title":"British Gynaecological Cancer Society (BGCS) epithelial ovarian\/fallopian tube\/primary peritoneal cancer guidelines: recommendations for practice","volume":"213","author":"Fotopoulou","year":"2017","journal-title":"European Journal of Obstetrics and Gynecology"},{"issue":"6B","key":"10.1002\/14651858.CD006119.pub4-BIB0041|cit41","first-page":"2683","article-title":"The measurement of plasma D-dimer DD levels in the follow-up of patients with ovarian cancer","volume":"15","author":"Gadducci","year":"1995","journal-title":"Anticancer Research"},{"issue":"5B","key":"10.1002\/14651858.CD006119.pub4-BIB0042|cit42","first-page":"3763\u20135","article-title":"Serum anti-p53 antibodies in the follow-up of patients with advanced ovarian carcinoma","volume":"18","author":"Gadducci","year":"1998","journal-title":"Anticancer Research"},{"issue":"4","key":"10.1002\/14651858.CD006119.pub4-BIB0043|cit43","first-page":"277","article-title":"The clinical relevance of serum CYFRA 21-1 assay in patients with ovarian cancer","volume":"11","author":"Gadducci","year":"2001","journal-title":"International Journal of Gynecological Cancer"},{"issue":"1","key":"10.1002\/14651858.CD006119.pub4-BIB0044|cit44","first-page":"21","article-title":"Surveillance procedures for patients treated for epithelial ovarian cancer: a review of the literature","volume":"17","author":"Gadducci","year":"2007","journal-title":"International Journal of Cancer"},{"issue":"4","key":"10.1002\/14651858.CD006119.pub4-BIB0045|cit45","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1016\/S0212-6982(03)72189-2","article-title":"F-18-FDG positron emission tomography in the diagnosis of ovarian recurrence. Comparison with CT scan and CA 125","volume":"22","author":"Garc\u00eda","year":"2003","journal-title":"Revista Espanola de Medicina Nuclear"},{"issue":"5","key":"10.1002\/14651858.CD006119.pub4-BIB0046|cit46","first-page":"320","article-title":"Tumor markers in the early diagnosis of recurrence in gynecologic neoplasms: combined determination of CA-125, CA 15-3, CA 724, SCC, 90 K","volume":"112","author":"Garzetti","year":"1991","journal-title":"Annali di Ostetricia, Ginecologia, Medicina Perinatale"},{"issue":"2","key":"10.1002\/14651858.CD006119.pub4-BIB0047|cit47","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1515\/cclm-2017-0019","article-title":"Liquid biopsy in ovarian cancer: recent advances on circulating tumor cells and circulating tumor DNA","volume":"56","author":"Giannopoulou","year":"2017","journal-title":"Clinical Chemistry and Laboratory Medicine"},{"key":"10.1002\/14651858.CD006119.pub4-BIB0048|cit48","doi-asserted-by":"crossref","unstructured":"Sung H Ferlay J Siegel RL Laversanne M Soerjomataram I Jemal A Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries CA: A Cancer Journal for Clinicians 2021 71 209 49","DOI":"10.3322\/caac.21660"},{"key":"10.1002\/14651858.CD006119.pub4-BIB0049|cit49","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1016\/S1470-2045(07)70273-5","article-title":"Management of asymptomatic patients on follow-up for ovarian cancer with rising CA-125 concentrations","volume":"8(9)","author":"Goonewardene","year":"2007","journal-title":"Lancet Oncology"},{"issue":"10","key":"10.1002\/14651858.CD006119.pub4-BIB0050|cit50","first-page":"746","article-title":"The value of FDG PET\/CT, ultrasound and CT in diagnosing recurrent ovarian carcinoma","volume":"77","author":"Grabiec","year":"2006","journal-title":"Ginekologia Polska"},{"issue":"7454","key":"10.1002\/14651858.CD006119.pub4-BIB0051|cit51","doi-asserted-by":"crossref","first-page":"1490","DOI":"10.1136\/bmj.328.7454.1490","article-title":"Grading quality of evidence and strength of recommendations","volume":"328","author":"GRADE Working Group","year":"2004","journal-title":"BMJ"},{"key":"10.1002\/14651858.CD006119.pub4-BIB0052|cit52","unstructured":"GRADEpro GDT McMaster University (developed by Evidence Prime)"},{"issue":"10","key":"10.1002\/14651858.CD006119.pub4-BIB0053|cit53","doi-asserted-by":"crossref","first-page":"1402","DOI":"10.1016\/S0959-8049(03)00307-1","article-title":"An international field study of the reliability and validity of a disease-specific questionnaire module (the QLQ-OV28) in assessing the quality of life of patients with ovarian cancer","volume":"39","author":"Greimel","year":"2003","journal-title":"European Journal of Cancer"},{"issue":"1","key":"10.1002\/14651858.CD006119.pub4-BIB0054|cit54","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1016\/j.ejogrb.2011.06.027","article-title":"Patients' view of routine follow-up after gynecological cancer treatment","volume":"159","author":"Greimel","year":"2011","journal-title":"European Journal of Obstetrics & Gynecology and Reproductive Biology"},{"issue":"4","key":"10.1002\/14651858.CD006119.pub4-BIB0055|cit55","first-page":"171","article-title":"Abdominal computerized tomography in the after-care of ovarian cancers","volume":"6","author":"Gritzmann","year":"1986","journal-title":"Digitale Bilddiagnostik"},{"key":"10.1002\/14651858.CD006119.pub4-BIB0056|cit56","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1136\/bmj.313.7058.665","article-title":"Routine follow up of breast cancer in primary care: randomised trial","volume":"313","author":"Grunfeld","year":"1996","journal-title":"BMJ"},{"issue":"23","key":"10.1002\/14651858.CD006119.pub4-BIB0057|cit57","doi-asserted-by":"crossref","first-page":"2123","DOI":"10.1056\/NEJMoa2103294","article-title":"Randomized trial of cytoreductive surgery for relapsed ovarian cancer","volume":"385","author":"Harter","year":"2021","journal-title":"New England Journal of Medicine"},{"issue":"2","key":"10.1002\/14651858.CD006119.pub4-BIB0058|cit58","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1016\/j.ejrad.2005.04.006","article-title":"Evaluation of integrated whole-body PET\/CT in the detection of recurrent ovarian cancer","volume":"56","author":"Hauth","year":"2005","journal-title":"European Journal of Radiology"},{"issue":"1","key":"10.1002\/14651858.CD006119.pub4-BIB0059|cit59","first-page":"6","article-title":"Predictive value of the tumor marker combination CA-125 and beta-2- microglobulin in ovarian cancer","volume":"114","author":"Hern\u00e1di","year":"1992","journal-title":"Zentralblatt f\u00fcr Gyn\u00e4kologie"},{"issue":"1-2","key":"10.1002\/14651858.CD006119.pub4-BIB0060|cit60","first-page":"263","article-title":"Significance of urinary neopterine in gynecological oncology: follow-up of patients with ovarian cancer","volume":"6","author":"Hetzel","year":"1983","journal-title":"Cancer Detection and Prevention"},{"key":"10.1002\/14651858.CD006119.pub4-BIB0061|cit61","unstructured":"Higgins JPT Altman DG Sterne JAC Chapter 8: Assessing risk of bias in included studies. In: Higgins JPT, Green S, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011) Available from training.cochrane.org\/handbook#previous-versions"},{"key":"10.1002\/14651858.CD006119.pub4-BIB0062|cit62","unstructured":"Higgins JPT Thomas J Chandler J Cumpston M Li T Page MJ Cochrane Handbook for Systematic Reviews of Interventions Version 6.3 (updated February 2022). Cochrane, 2022 Available from www.training.cochrane.org\/handbook"},{"issue":"2","key":"10.1002\/14651858.CD006119.pub4-BIB0063|cit63","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1097\/00000421-199104000-00003","article-title":"Clinical relevance of the CA 125 assay in monitoring of ovarian cancer patients","volume":"14","author":"Hising","year":"1991","journal-title":"American Journal of Clinical Oncology"},{"key":"10.1002\/14651858.CD006119.pub4-BIB0064|cit64","volume-title":"IARC Scientific Publication No 166","volume":"XI","author":"Bray","year":"2021"},{"issue":"9","key":"10.1002\/14651858.CD006119.pub4-BIB0065|cit65","first-page":"1799","article-title":"Tissue polypeptide antigen as a tumor marker for gynecologic malignancies","volume":"37","author":"Inoue","year":"1985","journal-title":"Nippon Sanka Fujinka Gakkai Zasshi"},{"issue":"6","key":"10.1002\/14651858.CD006119.pub4-BIB0066|cit66","first-page":"1256","article-title":"Diagnosis and follow-up of ovarian cancer by a combination assay of serum sialyl SSEA-1 antigen and CA125 levels","volume":"24","author":"Iwanari","year":"1989","journal-title":"Nippon Gan Chiryo Gakkai Shi"},{"issue":"9","key":"10.1002\/14651858.CD006119.pub4-BIB0067|cit67","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1016\/j.jacr.2007.05.019","article-title":"ACR appropriateness criteria on staging and follow-up of ovarian cancer","volume":"4","author":"Javitt","year":"2007","journal-title":"Journal of the American College of Radiology"},{"issue":"13","key":"10.1002\/14651858.CD006119.pub4-BIB0068|cit68","doi-asserted-by":"crossref","first-page":"1705","DOI":"10.1111\/1471-0528.15396","article-title":"Patient-initiated follow-up affects fear of recurrence and healthcare use: a randomised trial in early-stage endometrial cancer","volume":"125","author":"Jeppesen","year":"2018","journal-title":"British Journal of Obstetrics and Gynaecology"},{"issue":"17","key":"10.1002\/14651858.CD006119.pub4-BIB0069|cit69","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1007\/BF01732187","article-title":"Monoclonal antibodies in the diagnosis and follow-up of ovarian cancer CA 125 as a tumor marker A cooperative study of the Gynecologic Tumor Marker Group GTMG","volume":"64","author":"Kaesemann","year":"1986","journal-title":"Klinische Wochenschrift"},{"issue":"3","key":"10.1002\/14651858.CD006119.pub4-BIB0070|cit70","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1111\/j.1479-828X.1995.tb01986.x","article-title":"Follow-up of patients with gynaecological cancer","volume":"35","author":"Kerr-Wilson","year":"1995","journal-title":"Australian and New Zealand Journal of Obstetrics and Gynaecology"},{"issue":"3","key":"10.1002\/14651858.CD006119.pub4-BIB0071|cit71","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1136\/ijgc-00009577-200505000-00001","article-title":"The role of routine follow-up after gynecological malignancy","volume":"15","author":"Kew","year":"2005","journal-title":"International Journal of Gynecological Cancer"},{"key":"10.1002\/14651858.CD006119.pub4-BIB0072|cit72","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1136\/ijgc-00009577-200601000-00061","article-title":"Routine follow up after treatment for a gynaecological cancer: a survey of practice","volume":"16","author":"Kew","year":"2006","journal-title":"International Journal of Gynecological Cancer"},{"issue":"1","key":"10.1002\/14651858.CD006119.pub4-BIB0073|cit73","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1148\/radiology.159.1.3513245","article-title":"Ovarian carcinoma follow-up: US versus laparotomy","volume":"159","author":"Khan","year":"1986","journal-title":"Radiology"},{"issue":"3","key":"10.1002\/14651858.CD006119.pub4-BIB0074|cit74","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1002\/1097-0142(197409)34:3<542::AID-CNCR2820340311>3.0.CO;2-K","article-title":"Carcinoembryonic antigen by radioimmunoassay in the detection of recurrence during long-term follow-up of female genital cancer","volume":"34","author":"Khoo","year":"1974","journal-title":"Cancer"},{"issue":"6","key":"10.1002\/14651858.CD006119.pub4-BIB0075|cit75","doi-asserted-by":"crossref","first-page":"2471","DOI":"10.1002\/1097-0142(197906)43:6<2471::AID-CNCR2820430644>3.0.CO;2-E","article-title":"Predictive value of serial carcinoembryonic antigen levels in long-term follow-up of ovarian cancer","volume":"43","author":"Khoo","year":"1979","journal-title":"Cancer"},{"issue":"6","key":"10.1002\/14651858.CD006119.pub4-BIB0076|cit76","doi-asserted-by":"crossref","first-page":"868","DOI":"10.1097\/rct.0b013e31803e8c45","article-title":"Detection of recurrent ovarian cancer at MRI: comparison with integrated PET\/CT","volume":"31","author":"Kim","year":"2007","journal-title":"Journal of Computer Assisted Tomography"},{"issue":"8","key":"10.1002\/14651858.CD006119.pub4-BIB0077|cit77","doi-asserted-by":"crossref","first-page":"1439","DOI":"10.1007\/s00259-008-0776-3","article-title":"Performance of integrated FDG-PET\/contrast-enhanced CT in the diagnosis of recurrent ovarian cancer: comparison with integrated FDG-PET\/non-contrast-enhanced CT and enhanced CT","volume":"35","author":"Kitajima","year":"2008","journal-title":"European Journal of Nuclear Medicine & Molecular Imaging"},{"issue":"1","key":"10.1002\/14651858.CD006119.pub4-BIB0078|cit78","first-page":"15","article-title":"Clinical usefulness of serum sialyl Lex-i measurement in patients with ovarian cancer","volume":"41","author":"Kobayashi","year":"1989","journal-title":"Nippon Sanka Fujinka Gakkai Zasshi"},{"issue":"5","key":"10.1002\/14651858.CD006119.pub4-BIB0079|cit79","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1007\/s003300051000","article-title":"Value of 18F-FDG positron emission tomography, computed tomography, and magnetic resonance imaging in diagnosing primary and recurrent ovarian carcinoma","volume":"10","author":"Kubik","year":"2000","journal-title":"European Radiology"},{"issue":"9","key":"10.1002\/14651858.CD006119.pub4-BIB0080|cit80","doi-asserted-by":"crossref","first-page":"2228","DOI":"10.1002\/1097-0142(19871101)60:9<2228::AID-CNCR2820600921>3.0.CO;2-N","article-title":"The predictive value of a combination of tumor markers in monitoring patients with ovarian cancer","volume":"60","author":"Lahousen","year":"1987","journal-title":"Cancer"},{"key":"10.1002\/14651858.CD006119.pub4-BIB0081|cit81","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1186\/2046-4053-2-81","article-title":"Assessing and presenting summaries of evidence in Cochrane Reviews","volume":"2","author":"Langendam","year":"2013","journal-title":"Systematic Reviews"},{"key":"10.1002\/14651858.CD006119.pub4-BIB0082|cit82","doi-asserted-by":"crossref","first-page":"vi24","DOI":"10.1093\/annonc\/mdt333","article-title":"Newly diagnosed and relapsed epithelial ovarian carcinoma: ESMO clinical practice guidelines for diagnosis, treatment and follow-up","volume":"24 Suppl 6","author":"Ledermann","year":"2013","journal-title":"Annals of Oncology"},{"key":"10.1002\/14651858.CD006119.pub4-BIB0083|cit83","doi-asserted-by":"crossref","first-page":"e002859","DOI":"10.1136\/bmjopen-2013-002859","article-title":"Gynaecological cancer follow-up: national survey of current practice in the UK","volume":"3","author":"Leeson","year":"2013","journal-title":"BMJ Open"},{"issue":"5-6","key":"10.1002\/14651858.CD006119.pub4-BIB0084|cit84","first-page":"389","article-title":"Clinical correlations of carcinoembryonic antigen in post-operative patients with epithelial ovarian cancer","volume":"7","author":"Lenehan","year":"1986","journal-title":"Tumour Biology : The Journal of The International Society for Onco-developmental Biology and Medicine"},{"issue":"4C","key":"10.1002\/14651858.CD006119.pub4-BIB0085|cit85","first-page":"2303","article-title":"PET-CT in recurrent ovarian cancer: impact on treatment planning","volume":"28","author":"Lenhard","year":"2008","journal-title":"Anticancer Research"},{"issue":"2","key":"10.1002\/14651858.CD006119.pub4-BIB0086|cit86","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1148\/radiology.211.2.r99ma24519","article-title":"Treated ovarian cancer: comparison of MR imaging with serum CA-125 level and physical examination \u2013 a longitudinal study","volume":"211","author":"Low","year":"1999","journal-title":"Radiology"},{"issue":"5","key":"10.1002\/14651858.CD006119.pub4-BIB0087|cit87","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1007\/s00259-006-0306-0","article-title":"Integrated PET\/CT as a first-line re-staging modality in patients with suspected recurrence of ovarian cancer","volume":"34","author":"Mangili","year":"2007","journal-title":"European Journal of Nuclear Medicine & Molecular Imaging"},{"key":"10.1002\/14651858.CD006119.pub4-BIB0088|cit88","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1186\/2046-4053-3-82","article-title":"A checklist designed to aid consistency and reproducibility of GRADE assessments: development and pilot validation","volume":"3","author":"Meader","year":"2014","journal-title":"Systematic Reviews"},{"key":"10.1002\/14651858.CD006119.pub4-BIB0089|cit89","doi-asserted-by":"crossref","first-page":"1145","DOI":"10.1136\/bmj.325.7373.1145","article-title":"Nurse led follow-up and conventional medical follow-up in management of patients with lung cancer: randomised trial","volume":"325","author":"Moore","year":"2002","journal-title":"BMJ"},{"issue":"2","key":"10.1002\/14651858.CD006119.pub4-BIB0090|cit90","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1016\/j.ygyno.2020.09.007","article-title":"Minimally important differences for interpreting European Organisation for Research and Treatment of Cancer (EORTC) Quality of life Questionnaire core 30 scores in patients with ovarian cancer","volume":"159","author":"Musoro","year":"2020","journal-title":"Gynecologic Oncology"},{"issue":"6","key":"10.1002\/14651858.CD006119.pub4-BIB0091|cit91","doi-asserted-by":"crossref","first-page":"1449","DOI":"10.2214\/ajr.176.6.1761449","article-title":"Clinical value of positron emission tomography with FDG for recurrent ovarian cancer","volume":"176","author":"Nakamoto","year":"2001","journal-title":"American Journal of Roentgenology"},{"key":"10.1002\/14651858.CD006119.pub4-BIB0092|cit92","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1136\/ijgc-2019-001176","article-title":"British Gynaecological Cancer Society recommendations and guidance on patient-initiated follow-up (PIFU)","volume":"0","author":"Nwton","year":"2020","journal-title":"International Journal of Gynecological Cancer"},{"issue":"4A","key":"10.1002\/14651858.CD006119.pub4-BIB0093|cit93","first-page":"2513","article-title":"CASA and Ca 125 in diagnosis and follow-up of advanced ovarian cancer","volume":"19","author":"Oehler","year":"1999","journal-title":"Anticancer Research"},{"issue":"4","key":"10.1002\/14651858.CD006119.pub4-BIB0094|cit94","first-page":"363","article-title":"Assessment of ovarian tumors by transvaginal scanning and clinical significance of ultrasonic examination in postoperative follow up","volume":"40","author":"Okai","year":"1992","journal-title":"Rinsho Byori. The Japanese Journal of Clinical Pathology"},{"issue":"5","key":"10.1002\/14651858.CD006119.pub4-BIB0095|cit95","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1136\/ijgc-00009577-200109000-00002","article-title":"A critical evaluation of current protocols for the follow-up of women treated for gynecological malignancies: a pilot study","volume":"11","author":"Olaitan","year":"2001","journal-title":"International Journal of Gynecologic Cancer"},{"issue":"1","key":"10.1002\/14651858.CD006119.pub4-BIB0096|cit96","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1016\/j.ygyno.2005.11.046","article-title":"A study to evaluate the use of CA125 in ovarian cancer follow-up: a change in practice led by patient preference","volume":"101","author":"Palmer","year":"2006","journal-title":"Gynecologic Oncology"},{"issue":"3","key":"10.1002\/14651858.CD006119.pub4-BIB0097|cit97","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1016\/j.ygyno.2005.08.057","article-title":"The associations between knowledge, CA125 preoccupation, and distress in women with epithelial ovarian cancer","volume":"100","author":"Parker","year":"2006","journal-title":"Gynecologic Oncology"},{"issue":"24","key":"10.1002\/14651858.CD006119.pub4-BIB0098|cit98","doi-asserted-by":"crossref","first-page":"2815","DOI":"10.1002\/(SICI)1097-0258(19981230)17:24<2815::AID-SIM110>3.0.CO;2-8","article-title":"Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints","volume":"17","author":"Parmar","journal-title":"Statistics in Medicine"},{"issue":"5","key":"10.1002\/14651858.CD006119.pub4-BIB0099|cit99","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1016\/S1470-2045(21)00073-5","article-title":"Olaparib tablets as maintenance therapy in patients with platinum-sensitive relapsed ovarian cancer and a BRCA1\/2 mutation (SOLO2\/ENGOT-Ov21): a final analysis of a double-blind, randomised, placebo-controlled, phase 3 trial","volume":"22","author":"Poveda","year":"2021","journal-title":"Lancet Oncology"},{"issue":"4","key":"10.1002\/14651858.CD006119.pub4-BIB0100|cit100","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1097\/00004728-199307000-00021","article-title":"CT and MR accuracy in the detection of tumor recurrence in patients treated for ovarian cancer","volume":"17","author":"Prayer","year":"1993","journal-title":"Journal of Computer Assisted Tomography"},{"issue":"6","key":"10.1002\/14651858.CD006119.pub4-BIB0101|cit101","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1188\/11.CJON.625-632","article-title":"The management of anxiety and knowledge of serum CA-125 after an ovarian cancer diagnosis","volume":"15","author":"Reid","year":"2011","journal-title":"Clinical Journal of Oncology Nursing"},{"key":"10.1002\/14651858.CD006119.pub4-BIB0102|cit102","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1136\/bmj.324.7341.813","article-title":"Impact on survival of intensive follow up after curative resection for colorectal cancer: systematic review and meta-analysis of randomised trials","volume":"324","author":"Renehan","year":"2002","journal-title":"BMJ"},{"issue":"3","key":"10.1002\/14651858.CD006119.pub4-BIB0103|cit103","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1038\/sj.bjc.6602369","article-title":"Mechanisms of improved survival from intensive follow up in colorectal cancer: a hypothesis","volume":"92","author":"Renehan","year":"2005","journal-title":"British Journal of Cancer"},{"key":"10.1002\/14651858.CD006119.pub4-BIB0104|cit104","unstructured":"Review Manager 5 (RevMan 5) The Cochrane Collaboration 2020"},{"key":"10.1002\/14651858.CD006119.pub4-BIB0105|cit105","unstructured":"Review Manager Web (RevMan Web) The Cochrane Collaboration 2023"},{"issue":"4","key":"10.1002\/14651858.CD006119.pub4-BIB0106|cit106","doi-asserted-by":"crossref","first-page":"353\u201366","DOI":"10.1080\/13698570903013623","article-title":"Future disorientation following gynaecological cancer: women\u2019s conceptualisation of risk after a life-threatening illness","volume":"11","author":"Roberts","year":"2009","journal-title":"Health, Risk & Society"},{"issue":"3","key":"10.1002\/14651858.CD006119.pub4-BIB0107|cit107","first-page":"1015\u201322","article-title":"Role of IGF-I in primary ovarian cancer - a study of the OVCAD European Consortium","volume":"36","author":"Rohr","year":"2016","journal-title":"Anticancer Research"},{"issue":"9021","key":"10.1002\/14651858.CD006119.pub4-BIB0108|cit108","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1016\/S0140-6736(05)66133-8","article-title":"Use of CA 125 in follow-up of ovarian cancer","volume":"348","author":"Rustin","year":"1996","journal-title":"Lancet"},{"issue":"8","key":"10.1002\/14651858.CD006119.pub4-BIB0109|cit109","doi-asserted-by":"crossref","first-page":"e055460","DOI":"10.1136\/bmjopen-2021-055460","article-title":"Factors influencing the translation of shared cancer follow-up care into clinical practice: a systematic review","volume":"12","author":"Sandell","year":"2022","journal-title":"BMJ Open"},{"issue":"7","key":"10.1002\/14651858.CD006119.pub4-BIB0110|cit110","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1200\/JCO.19.02748","article-title":"Lung cancer surveillance after definitive curative-intent therapy: ASCO guideline","volume":"38","author":"Schneider","year":"2020","journal-title":"Journal of Clinical Oncology"},{"issue":"10","key":"10.1002\/14651858.CD006119.pub4-BIB0111|cit111","doi-asserted-by":"crossref","first-page":"3474","DOI":"10.1158\/1078-0432.CCR-03-0365","article-title":"Osteopontin as an adjunct to CA125 in detecting recurrent ovarian cancer","volume":"10","author":"Schorge","year":"2004","journal-title":"Clinical Cancer Research: An Official Journal of the American Association for Cancer Research"},{"key":"10.1002\/14651858.CD006119.pub4-BIB0112|cit112","unstructured":"Sch\u00fcnemann HJ Higgins JP Vist GE Glasziou P Akl EA Skoetz N Chapter 14: Completing \u2018Summary of findings\u2019 tables and grading the certainty of the evidence. In: Higgins JPT, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, et al, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 6.3 (updated February 2022) Available from www.training.cochrane.org\/handbook"},{"issue":"4","key":"10.1002\/14651858.CD006119.pub4-BIB0113|cit113","doi-asserted-by":"crossref","first-page":"857","DOI":"10.2214\/ajr.177.4.1770857","article-title":"Value of chest CT scans in routine ovarian carcinoma follow-up","volume":"177","author":"Sella","year":"2001","journal-title":"American Journal of Roentgenology"},{"issue":"4","key":"10.1002\/14651858.CD006119.pub4-BIB0114|cit114","first-page":"554","article-title":"Significance of immunosuppressive acidic protein in the diagnosis and follow-up of patients with ovarian cancer, in particular as a marker for chemotherapeutic effects","volume":"38","author":"Shimizu","year":"1986","journal-title":"Nippon Sanka Fujinka Gakkai Zasshi"},{"issue":"1-2","key":"10.1002\/14651858.CD006119.pub4-BIB0115|cit115","first-page":"53","article-title":"Follow-up laparoscopy in patients with ovarian cancer","volume":"19","author":"Shinozuka","year":"1994","journal-title":"The Tokai Journal of Experimental and Clinical Medicine"},{"issue":"1","key":"10.1002\/14651858.CD006119.pub4-BIB0116|cit116","first-page":"17","article-title":"Cancer statistics","volume":"73","author":"Siegel","year":"2023","journal-title":"CA: A Cancer Journal for Clinicians"},{"issue":"3","key":"10.1002\/14651858.CD006119.pub4-BIB0117|cit117","first-page":"1127","article-title":"Tissue polypeptide specific antigen and cancer associated serum antigen in the follow-up of ovarian cancer","volume":"15","author":"Sliutz","year":"1995","journal-title":"Anticancer Research"},{"issue":"3","key":"10.1002\/14651858.CD006119.pub4-BIB0118|cit118","first-page":"213","article-title":"Feasibility of peritoneal washing cytology through the totally implanted reservoir for early detection of peritoneal recurrence of ovarian cancer","volume":"48","author":"Sugiyama","year":"1996","journal-title":"Nippon Sanka Fujinka Gakkai Zasshi"},{"issue":"2","key":"10.1002\/14651858.CD006119.pub4-BIB0119|cit119","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD007929.pub4","article-title":"Poly(ADP-ribose) polymerase (PARP) inhibitors for the treatment of ovarian cancer","author":"Tattersall","year":"2022","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"3","key":"10.1002\/14651858.CD006119.pub4-BIB0120|cit120","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1002\/(SICI)1097-0215(19980619)79:3<241::AID-IJC5>3.0.CO;2-P","article-title":"Tissue polypeptide specific antigen in the follow-up of ovarian and cervical cancer patients","volume":"79","author":"Tempfer","year":"1998","journal-title":"International Journal of Cancer. Journal International du Cancer"},{"issue":"5","key":"10.1002\/14651858.CD006119.pub4-BIB0121|cit121","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1046\/j.1469-0705.2002.00693.x","article-title":"Detection of central pelvic recurrent disease with transvaginal color Doppler ultrasound in women treated for gynecological malignancy","volume":"19","author":"Testa","year":"2002","journal-title":"Ultrasound in Obstetrics & Gynecology"},{"issue":"3","key":"10.1002\/14651858.CD006119.pub4-BIB0122|cit122","doi-asserted-by":"crossref","first-page":"696","DOI":"10.1016\/j.ygyno.2005.07.116","article-title":"The role of sonographic examination in the follow-up of gynecological neoplasms","volume":"99","author":"Testa","year":"2005","journal-title":"Gynecologic Oncology"},{"issue":"1","key":"10.1002\/14651858.CD006119.pub4-BIB0123|cit123","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.ygyno.2006.10.060","article-title":"Clinical use of combined positron emission tomography and computed tomography FDG-PET\/CT in recurrent ovarian cancer","volume":"105","author":"Thrall","year":"2007","journal-title":"Gynecologic Oncology"},{"key":"10.1002\/14651858.CD006119.pub4-BIB0124|cit124","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1186\/1745-6215-8-16","article-title":"Practical methods for incorporating summary time-to-event data into meta-analysis","volume":"8","author":"Tierney","year":"2007","journal-title":"Trials"},{"issue":"6","key":"10.1002\/14651858.CD006119.pub4-BIB0125|cit125","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1007\/s00259-001-0750-9","article-title":"Ovarian cancer recurrence: role of whole-body positron emission tomography using 2-fluorine-18-fluoro-2-deoxy- D-glucose","volume":"29","author":"Torizuka","year":"2002","journal-title":"European Journal of Nuclear Medicine and Molecular Imaging"},{"issue":"3 pt2","key":"10.1002\/14651858.CD006119.pub4-BIB0126|cit126","first-page":"S1","article-title":"The NIH consensus conference on ovarian cancer: screening, treatment, and follow-up","volume":"55","author":"Trimble","year":"1994","journal-title":"Gynecologic Oncology"},{"issue":"3","key":"10.1002\/14651858.CD006119.pub4-BIB0127|cit127","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1080\/003655102317475434","article-title":"Serum tumor marker CA 125 for monitoring ovarian cancer during follow-up","volume":"62","author":"Tuxen","year":"2002","journal-title":"Scandinavian Journal of Clinical and Laboratory Investigation"},{"issue":"1","key":"10.1002\/14651858.CD006119.pub4-BIB0128|cit128","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1016\/0090-8258(80)90064-5","article-title":"Follow-up study of ovarian carcinoma by cytology of cul-de-sac aspirates","volume":"10","author":"VillaSanta","year":"1980","journal-title":"Gynecologic Oncology"},{"issue":"2","key":"10.1002\/14651858.CD006119.pub4-BIB0129|cit129","first-page":"205","article-title":"Tumor marker CA 125 in diagnosis, monitoring management and follow-up of patients with ovarian tumors","volume":"13","author":"Vinokurov","year":"1992","journal-title":"European Journal of Gynaecological Oncology"},{"key":"10.1002\/14651858.CD006119.pub4-BIB0130|cit130","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.ejogrb.2003.10.029","article-title":"Post-therapy surveillance and after-care in ovarian cancer","volume":"114","author":"Von Georgi","year":"2004","journal-title":"European Journal of Obstetrics & Gynecology and Reproductive Biology"},{"issue":"2","key":"10.1002\/14651858.CD006119.pub4-BIB0131|cit131","first-page":"1015","article-title":"Ultrasonographic-guided pervaginal cul-de-sac cytology in the follow-up of ovarian carcinoma","volume":"27","author":"Vuento","year":"2007","journal-title":"Anticancer Research"},{"issue":"12","key":"10.1002\/14651858.CD006119.pub4-BIB0132|cit132","first-page":"1523\u201331","article-title":"The value of serum tissue polypeptide specific antigen TPS concentration in therapeutic monitoring of patients with epithelial malignant ovarian neoplasms","volume":"71","author":"Zakrzewska","year":"2000","journal-title":"Ginekologia Polska"},{"issue":"6","key":"10.1002\/14651858.CD006119.pub4-BIB0133|cit133","first-page":"356","article-title":"Role of positron emission tomography in detecting recurrent epithelial ovarian carcinoma","volume":"37","author":"Zhu","year":"2002","journal-title":"Zhonghua Fu Chan Ke za Zhi"},{"issue":"6","key":"10.1002\/14651858.CD006119.pub4-BIB0134|cit134","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1111\/j.1600-0447.1983.tb09716.x","article-title":"The hospital anxiety and depression scale","volume":"67","author":"Zigmond","year":"1983","journal-title":"Acta Psychiatrica Scandinavica"},{"issue":"2","key":"10.1002\/14651858.CD006119.pub4-BIB0135|cit135","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1006\/gyno.2001.6386","article-title":"2-Fluorine-18-fluoro-2-deoxy-d-glucose positron emission tomography in the diagnosis of recurrent ovarian cancer","volume":"83","author":"Zimny","year":"2001","journal-title":"Gynecologic Oncology"},{"issue":"9","key":"10.1002\/14651858.CD006119.pub4-BIB0136|cit136","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD006119.pub3","article-title":"Evaluation of follow-up strategies for patients with epithelial ovarian cancer following completion of primary treatment","author":"Clarke","year":"2014","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"6","key":"10.1002\/14651858.CD006119.pub4-BIB0137|cit137","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD006119.pub2","article-title":"Evaluation of follow-up strategies for patients with epithelial ovarian cancer following completion of primary treatment","author":"Kew","year":"2011","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"3","key":"10.1002\/14651858.CD006119.pub4-BIB0138|cit138","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD006119","article-title":"Evaluation of follow-up strategies for patients with epithelial ovarian cancer following completion of primary treatment","author":"Naik","year":"2006","journal-title":"Cochrane Database of Systematic Reviews"}],"container-title":["Cochrane Database of Systematic Reviews"],"original-title":[],"language":"en","deposited":{"date-parts":[[2025,7,18]],"date-time":"2025-07-18T14:47:45Z","timestamp":1752850065000},"score":1,"resource":{"primary":{"URL":"http:\/\/doi.wiley.com\/10.1002\/14651858.CD006119.pub4"}},"subtitle":[],"editor":[{"name":"Cochrane Gynaecological, Neuro-oncology and Orphan Cancer Group","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2023,8,31]]},"references-count":138,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2023,8]]}},"URL":"https:\/\/doi.org\/10.1002\/14651858.cd006119.pub4","relation":{},"ISSN":["1465-1858"],"issn-type":[{"value":"1465-1858","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,8,31]]}}}